BR112017010889A2 - métodos para purificação para remover as impurezas de íons de metal de um complexo de metal de lantanídeo de um metal de lantanídeo, para preparação de uma formulação farmacêutica líquida e de um agente de contraste de formação de imagem de ressonância magnética, resina de eliminação, e, uso de uma resina de eliminação. - Google Patents
métodos para purificação para remover as impurezas de íons de metal de um complexo de metal de lantanídeo de um metal de lantanídeo, para preparação de uma formulação farmacêutica líquida e de um agente de contraste de formação de imagem de ressonância magnética, resina de eliminação, e, uso de uma resina de eliminação.Info
- Publication number
- BR112017010889A2 BR112017010889A2 BR112017010889-5A BR112017010889A BR112017010889A2 BR 112017010889 A2 BR112017010889 A2 BR 112017010889A2 BR 112017010889 A BR112017010889 A BR 112017010889A BR 112017010889 A2 BR112017010889 A2 BR 112017010889A2
- Authority
- BR
- Brazil
- Prior art keywords
- lanthanide metal
- elimination resin
- lanthanide
- preparing
- purification
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
- A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
- A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
- A61K49/108—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA the metal complex being Gd-DOTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Abstract
a presente invenção refere-se a um método de remoção de impurezas de íons de metal, tais como cálcio, a partir de complexos de metal de lantanídeo de quelantes macrocíclicos. o método usa uma resina de eliminação para remover íons de metal, deslocados do quelante, por um excesso de íons de lantanídeo. é também proporcionado um método de preparação de agentes de contraste de mri, a partir do complexo de metal de lantanídeo purificado, pela adição de um excesso de quelante definido.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1421162.7 | 2014-11-28 | ||
| GBGB1421162.7A GB201421162D0 (en) | 2014-11-28 | 2014-11-28 | Lanthanide complex formulations |
| PCT/EP2015/077970 WO2016083605A1 (en) | 2014-11-28 | 2015-11-27 | Lanthanide complex formulations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112017010889A2 true BR112017010889A2 (pt) | 2018-02-14 |
| BR112017010889B1 BR112017010889B1 (pt) | 2022-02-22 |
Family
ID=52349617
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112017010889-5A BR112017010889B1 (pt) | 2014-11-28 | 2015-11-27 | Métodos para purificação para remover as impurezas de íons de metal de um complexo demetal de lantanídeo de um metal de lantanídeo, para preparação de uma formulação farmacêuticalíquida e de um agente de contraste de formação de imagem de ressonância magnética, resina deeliminação, e, uso da resina de eliminação |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US10576169B2 (pt) |
| EP (1) | EP3224250A1 (pt) |
| JP (1) | JP6846347B2 (pt) |
| KR (2) | KR20170092546A (pt) |
| CN (1) | CN107001293B (pt) |
| AU (1) | AU2015352426B2 (pt) |
| BR (1) | BR112017010889B1 (pt) |
| CA (1) | CA2967877A1 (pt) |
| GB (1) | GB201421162D0 (pt) |
| MX (1) | MX2017006800A (pt) |
| RU (1) | RU2707070C2 (pt) |
| WO (1) | WO2016083605A1 (pt) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201421162D0 (en) | 2014-11-28 | 2015-01-14 | Ge Healthcare As | Lanthanide complex formulations |
| CN110114093A (zh) * | 2016-12-29 | 2019-08-09 | 创意有限责任公司 | 无溶剂钆造影剂 |
| US20190269805A1 (en) | 2016-12-29 | 2019-09-05 | Inventure, LLC | Solvent-free gadolinium contrast agents |
| US11654424B1 (en) * | 2019-06-10 | 2023-05-23 | Triad National Security, Llc | Method embodiments for making lanthanide metal complexes from lanthanide metal oxides and separating the same from heavy lanthanide metal oxides, actinide oxides, and non-lanthanide rare earth element oxides |
| GB201919073D0 (en) * | 2019-12-20 | 2020-02-05 | Ge Healthcare As | Novel manufacturing process |
| CN113527222B (zh) * | 2020-04-21 | 2023-06-13 | 威智医药股份有限公司 | 一种钆特酸葡甲胺的制备方法 |
| CN113801071B (zh) * | 2021-09-14 | 2023-04-07 | 安徽普利药业有限公司 | 一种钆特酸葡甲胺的精制方法 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4028234A (en) | 1974-06-06 | 1977-06-07 | Aerojet-General Corporation | Buffering agents |
| US4647447A (en) * | 1981-07-24 | 1987-03-03 | Schering Aktiengesellschaft | Diagnostic media |
| DE3640708C2 (de) | 1986-11-28 | 1995-05-18 | Schering Ag | Verbesserte metallhaltige Pharmazeutika |
| WO1989012631A1 (en) * | 1988-06-24 | 1989-12-28 | The Dow Chemical Company | Macrocyclic bifunctional chelants, complexes thereof and their antibody conjugates |
| IT1269839B (it) * | 1994-05-26 | 1997-04-15 | Bracco Spa | Coniugati di acidi biliari, loro derivati con complessi metallici e relativi usi |
| US5665239A (en) | 1996-01-16 | 1997-09-09 | Culligan International Company | Processes for deionization and demineralization of fluids |
| IT1292128B1 (it) | 1997-06-11 | 1999-01-25 | Bracco Spa | Processo per la preparazione di chelanti macrociclici e loro chelati con ioni metallici paramagnetici |
| FR2772025B1 (fr) | 1997-12-10 | 2000-03-03 | Guerbet Sa | Chelates metalliques de macrocycles polyaminocarboxyliques et leur application a l'imagerie par resonance magnetique |
| US20040167330A1 (en) | 2001-07-17 | 2004-08-26 | Ivan Lukes | Novel chelating agents and conjugates thereof, their synthesis and use as diagnois and therapeutic agents |
| WO2008144728A1 (en) * | 2007-05-21 | 2008-11-27 | Bracco Imaging S.P.A. | Conjugates which bind a blood protein such as human serum albumin and methods of using the same in diagnostic and therapeutic applications |
| US20090208421A1 (en) | 2008-02-19 | 2009-08-20 | Dominique Meyer | Process for preparing a pharmaceutical formulation of contrast agents |
| FR2945448B1 (fr) | 2009-05-13 | 2012-08-31 | Guerbet Sa | Procede de preparation d'une formulation pharmaceutique de chelate de lanthanide sous forme de poudre. |
| EP2338874A1 (en) | 2009-12-16 | 2011-06-29 | Bracco Imaging S.p.A | Process for the preparation of chelated compounds |
| WO2014114664A1 (en) | 2013-01-28 | 2014-07-31 | Agfa Healthcare | Process for producing 1, 4, 7, 10-tetraazacyclododecane-1, 4, 7, 10-tetraacetic acid and complexes thereof |
| EP2786768A1 (en) | 2013-04-04 | 2014-10-08 | Agfa Healthcare | Process for preparing a material comprising a macrocyclic ligand and for producing a pharmaceutical formulation comprising said ligand with a lanthanide |
| GB201421162D0 (en) | 2014-11-28 | 2015-01-14 | Ge Healthcare As | Lanthanide complex formulations |
-
2014
- 2014-11-28 GB GBGB1421162.7A patent/GB201421162D0/en not_active Ceased
-
2015
- 2015-11-27 JP JP2017526514A patent/JP6846347B2/ja active Active
- 2015-11-27 KR KR1020177014038A patent/KR20170092546A/ko not_active IP Right Cessation
- 2015-11-27 BR BR112017010889-5A patent/BR112017010889B1/pt active IP Right Grant
- 2015-11-27 RU RU2017116220A patent/RU2707070C2/ru active
- 2015-11-27 CA CA2967877A patent/CA2967877A1/en active Pending
- 2015-11-27 EP EP15804098.0A patent/EP3224250A1/en active Pending
- 2015-11-27 AU AU2015352426A patent/AU2015352426B2/en active Active
- 2015-11-27 CN CN201580064643.5A patent/CN107001293B/zh active Active
- 2015-11-27 US US15/531,431 patent/US10576169B2/en active Active
- 2015-11-27 WO PCT/EP2015/077970 patent/WO2016083605A1/en active Application Filing
- 2015-11-27 MX MX2017006800A patent/MX2017006800A/es unknown
- 2015-11-27 KR KR1020237028434A patent/KR102608019B1/ko active IP Right Grant
-
2020
- 2020-01-24 US US16/752,307 patent/US11400172B2/en active Active
-
2022
- 2022-06-28 US US17/851,454 patent/US20220354971A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3224250A1 (en) | 2017-10-04 |
| RU2017116220A (ru) | 2018-12-28 |
| KR20170092546A (ko) | 2017-08-11 |
| JP6846347B2 (ja) | 2021-03-24 |
| KR20230125860A (ko) | 2023-08-29 |
| US10576169B2 (en) | 2020-03-03 |
| US11400172B2 (en) | 2022-08-02 |
| AU2015352426A1 (en) | 2017-05-25 |
| CN107001293A (zh) | 2017-08-01 |
| KR102608019B1 (ko) | 2023-11-30 |
| US20220354971A1 (en) | 2022-11-10 |
| WO2016083605A1 (en) | 2016-06-02 |
| US20200155712A1 (en) | 2020-05-21 |
| BR112017010889B1 (pt) | 2022-02-22 |
| CA2967877A1 (en) | 2016-06-02 |
| AU2015352426B2 (en) | 2020-03-05 |
| CN107001293B (zh) | 2023-09-19 |
| MX2017006800A (es) | 2017-09-08 |
| GB201421162D0 (en) | 2015-01-14 |
| RU2017116220A3 (pt) | 2019-02-25 |
| JP2017535553A (ja) | 2017-11-30 |
| US20170258945A1 (en) | 2017-09-14 |
| RU2707070C2 (ru) | 2019-11-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112017010889A2 (pt) | métodos para purificação para remover as impurezas de íons de metal de um complexo de metal de lantanídeo de um metal de lantanídeo, para preparação de uma formulação farmacêutica líquida e de um agente de contraste de formação de imagem de ressonância magnética, resina de eliminação, e, uso de uma resina de eliminação. | |
| NZ731095A (en) | Compositions and methods for treating cns disorders | |
| PH12015502615B1 (en) | Chemical compounds | |
| JO3724B1 (ar) | تركيبات وطرق لعلاج اضطربات الجهاز العصبي المركزي (cns) | |
| PH12017500393A1 (en) | Pyrrolopyrimidines for use in influenza virus infection | |
| MY191590A (en) | 9h-pyrrolo-dipyridine derivatives | |
| PL3785733T3 (pl) | Kompozycja farmaceutyczna do leczenia autyzmu | |
| MX2016015434A (es) | Combinaciones farmaceuticas para tratar cancer. | |
| SV2017005462A (es) | Compuestos de isoxazol de ácido hidroxámico como inhibidores de lpxc | |
| IN2015DN01164A (pt) | ||
| MX2017006799A (es) | Formulaciones de complejo de metal. | |
| IN2015DN01165A (pt) | ||
| MX2015011193A (es) | Compuestos antivirales. | |
| PH12017500533A1 (en) | 1-alkyl-6-oxo-1, 6-dihydropyridin-3-yl compounds and use as sgrm modulators | |
| FR3026099B1 (fr) | Procedes de recuperation selective de terres rares presentes dans des phases aqueuses acides issues du traitement d'aimants permanents usages ou rebutes | |
| BR112017005242A2 (pt) | composto, composição farmacêutica, e, composto para uso. | |
| MX362879B (es) | Usos novedosos. | |
| PH12017500159B1 (en) | [1,2,4]triazolo[4,3-b]pyridazines for use in the treatment of proliferative diseases | |
| BR112015026840A2 (pt) | composto, sal farmaceuticamente aceitável, composição farmacêutica, uso de um composto, e, método prevenir ou tratar hiperfosfatemia | |
| EP2893936A4 (en) | METHOD AND AGENT FOR THE TREATMENT AND PROPHYLAXIS OF DISEASES MEDIATED BY (+) RNA-CONTAINING VIRUSES | |
| MX2015011198A (es) | Compuestos antivirales. | |
| GB2515440A (en) | Vesicular formulations | |
| IN2015DN02109A (pt) | ||
| BR112018006189A2 (pt) | compostos da fórmula, composição farmacêutica, métodos de tratamento de uma doença, de diminuição do fluxo de íons e de tratamento de prurido em um mamífero, método para tratamento de dores em um mamífero e uso de um composto | |
| MX2015010892A (es) | Compuestos antivirales. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 27/11/2015, OBSERVADAS AS CONDICOES LEGAIS. |